Norberto Ortego-Centeno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8294083/publications.pdf

Version: 2024-02-01

139	4,714	109137	118652
papers	citations	35 h-index	62 g-index

171	171	171	6671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics, 2010, 42, 426-429.	9.4	351
2	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	5.8	314
3	Association of a functional single-nucleotide polymorphism ofPTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 219-224.	6.7	275
4	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genetics, 2011, 7, e1002178.	1.5	201
5	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
6	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
7	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	0.4	133
8	A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Human Molecular Genetics, 2008, 18, 569-579.	1.4	106
9	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	1.4	104
10	SomaticNLRP3mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Annals of the Rheumatic Diseases, 2015, 74, 603-610.	0.5	104
11	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	1.4	98
12	Registry of the Spanish Network for Systemic Sclerosis: Clinical Pattern According to Cutaneous Subsets and Immunological Status. Seminars in Arthritis and Rheumatism, 2012, 41, 789-800.	1.6	92
13	Treatment of therapy-resistant sarcoidosis with adalimumab. Clinical Rheumatology, 2006, 25, 596-597.	1.0	91
14	Anti-TNF-Î± therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Seminars in Arthritis and Rheumatism, 2015, 45, 361-368.	1.6	78
15	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
16	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.5	63
17	Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 114-119.	0.5	62
18	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	2.9	60

#	Article	IF	Citations
19	A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 286-294.	0.5	58
20	Confirmation ofTNIP1but notRHOBandPSORS1C1as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.5	56
21	Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Human Molecular Genetics, 2009, 18, 3739-3748.	1.4	54
22	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Research and Therapy, 2011, 13, R112.	1.6	53
23	Proteomic analysis of plasma from patients with systemic lupus erythematosus: Increased presence of haptoglobin Î±2 polypeptide chains over the Î±1 isoforms. Proteomics, 2006, 6, S282-S292.	1.3	51
24	HLA and non-HLA genes in BehÃ§etâ€™s disease: a multicentric study in the Spanish population. Arthritis Research and Therapy, 2013, 15, R145.	1.6	50
25	Genetic Analysis with the Immunochip Platform in BehÃ§et Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci. PLoS ONE, 2016, 11, e0161305.	1.1	48
26	Association of a CD24 gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 3080-3086.	6.7	47
27	Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators of Inflammation, 2013, 2013, 1-6.	1.4	47
28	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	2.9	46
29	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	2.5	46
30	Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: BehÃ§etâ€™s Disease, Sarcoidosis, and Noninfectious Uveitis. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	45
31	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Scientific Reports, 2017, 7, 5088.	1.6	44
32	Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.5	41
33	Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1305-1313.	0.9	39
34	Vitamin D Deficiency in a Cohort of Patients with Systemic Scleroderma from the South of Spain. Journal of Rheumatology, 2010, 37, 1355-1355.	1.0	38
35	Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Cytokine, 2013, 62, 232-243.	1.4	37
36	Brief Report: Association of HLAâ€“DRB1*01 With IgA Vasculitis (Henochâ€Schönlein). Arthritis and Rheumatology, 2015, 67, 823-827.	2.9	35

#	Article	IF	Citations
37	MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Human Immunology, 2007, 68, 610-615.	1.2	33
38	Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein. Annals of the Rheumatic Diseases, 2012, 71, 1219-1226.	0.5	33
39	Association of HLA-B*41:02 with Henoch-SchÃ¶nlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	1.6	33
40	Promoter Insertion/Deletion in the IRF5 Gene Is Highly Associated with Susceptibility to Systemic Lupus Erythematosus in Distinct Populations, But Exerts a Modest Effect on Gene Expression in Peripheral Blood Mononuclear Cells. Journal of Rheumatology, 2010, 37, 574-578.	1.0	32
41	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcetâ€™s disease. Human Immunology, 2013, 74, 230-233.	1.2	30
42	Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.5	30
43	Epistatic Interaction of ERAP1 and HLA-B in BehÃ§et Disease: A Replication Study in the Spanish Population. PLoS ONE, 2014, 9, e102100.	1.1	30
44	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.4	30
45	Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	2.9	29
46	Mutational profile of rare variants in inflammasome-related genes in BehÃ§et disease: A Next Generation Sequencing approach. Scientific Reports, 2017, 7, 8453.	1.6	29
47	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clinical Rheumatology, 2018, 37, 999-1009.	1.0	27
48	Evidence of New Risk Genetic Factor to Systemic Lupus Erythematosus: The UBASH3A Gene. PLoS ONE, 2013, 8, e60646.	1.1	27
49	Adalimumab Treatment for SAPHO Syndrome. Acta Dermato-Venereologica, 2010, 90, 301-302.	0.6	26
50	Altered AKT1 and MAPK1 Gene Expression on Peripheral Blood Mononuclear Cells and Correlation with T-Helper-Transcription Factors in Systemic Lupus Erythematosus Patients. Mediators of Inflammation, 2012, 2012, 1-14.	1.4	26
51	PXKlocus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility geneABHD6. Annals of the Rheumatic Diseases, 2015, 74, e14-e14.	0.5	24
52	Association of haplotypes of the TLR8 locus with susceptibility to Crohn's and BehÃ§et's diseases. Clinical and Experimental Rheumatology, 2015, 33, S117-22.	0.4	24
53	Evidence of association of theNLRP1gene with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 628-630.	0.5	23
54	Increased association of CD38 with lipid rafts in T cells from patients with systemic lupus erythematosus and in activated normal T cells. Molecular Immunology, 2006, 43, 1029-1039.	1.0	21

#	Article	IF	Citations
55	Adalimumab Therapy for Refractory Uveitis: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 613-614.	0.6	21
56	Increased expression and phosphorylation of the two S100A9 isoforms in mononuclear cells from patients with systemic lupus erythematosus: A proteomic signature for circulating low-density granulocytes. Journal of Proteomics, 2012, 75, 1778-1791.	1.2	21
57	Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. Journal of Rheumatology, 2003, 30, 1657-8.	1.0	21
58	Prevalence of exercise pulmonary arterial hypertension in scleroderma. Journal of Rheumatology, 2008, 35, 1812-6.	1.0	21
59	Influence of CD40 rs1883832 Polymorphism in Susceptibility to and Clinical Manifestations of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2076-2080.	1.0	19
60	Identification of HAVCR1 gene haplotypes associated with mRNA expression levels and susceptibility to autoimmune diseases. Human Genetics, 2010, 128, 221-229.	1.8	18
61	Analysis of the REL polymorphism rs13031237 in autoimmune diseases. Annals of the Rheumatic Diseases, 2011, 70, 711-712.	0.5	18
62	Association of theFCGR3A-158F/V Gene Polymorphism with the Response to Rituximab Treatment in Spanish Systemic Autoimmune Disease Patients. DNA and Cell Biology, 2012, 31, 1671-1677.	0.9	18
63	New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. Journal of Medical Genetics, 2017, 54, 38-46.	1.5	18
64	Association Between â˜'174 Interleukin-6 Gene Polymorphism and Biological Response to Rituximab in Several Systemic Autoimmune Diseases. DNA and Cell Biology, 2012, 31, 1486-1491.	0.9	17
65	GIMAP and BehÃ§et disease: no association in the European population: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1433-1434.	0.5	17
66	Variants of the IFI16 Gene Affecting the Levels of Expression of mRNA Are Associated with Susceptibility to BehÃ§et Disease. Journal of Rheumatology, 2015, 42, 695-701.	1.0	17
67	Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis. American Journal of Therapeutics, 2016, 23, e1193-e1196.	0.5	17
68	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	1.1	17
69	Recurrent Telangiectasias on the Cheek: Angiolupoid Sarcoidosis. American Journal of Medicine, 2010, 123, e7-e8.	0.6	16
70	Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. Autoimmunity Reviews, 2017, 16, 796-802.	2.5	16
71	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Seminars in Arthritis and Rheumatism, 2018, 47, 849-857.	1.6	16
72	IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports, 2013, 40, 4851-4856.	1.0	15

#	Article	IF	Citations
73	Analyses of hair and salivary cortisol for evaluating hypothalamicâ€“pituitaryâ€“adrenal axis activation in patients with autoimmune disease. Stress, 2017, 20, 541-548.	0.8	15
74	Analysis of Ancestral and Functionally Relevant CD5 Variants in Systemic Lupus Erythematosus Patients. PLoS ONE, 2014, 9, e113090.	1.1	15
75	Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 477.	0.2	14
76	Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions. Clinical and Experimental Rheumatology, 2012, 30, 905-11.	0.4	14
77	Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A â€œReal-Lifeâ€•Study. Journal of Osteoporosis, 2015, 2015, 1-7.	0.1	13
78	Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. Journal of Rheumatology, 2015, 42, 2327-2331.	1.0	13
79	Tongue infarction as first symptom of temporal arteritis. Rheumatology International, 2012, 32, 799-800.	1.5	12
80	Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. BMC Medical Genetics, 2013, 14, 52.	2.1	12
81	Serosal involvement in IgG4-related disease: report of two cases and review of the literature. Rheumatology International, 2016, 36, 1033-1041.	1.5	12
82	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	1.6	12
83	Interleukin 1 beta (IL1ÃŸ) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-SchÃ¶nlein purpura. Clinical and Experimental Rheumatology, 2016, 34, S84-8.	0.4	12
84	Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. Clinical Rheumatology, 2006, 25, 407-408.	1.0	11
85	Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by Sildenafil. Liver Transplantation, 2006, 12, 690-691.	1.3	11
86	Health-related Internet use by lupus patients in southern Spain. Clinical Rheumatology, 2014, 33, 567-573.	1.0	11
87	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-SchÃ¶nlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	1.6	11
88	Use of Adalimumab in Poststreptococcal Reactive Arthritis. Journal of Clinical Rheumatology, 2007, 13, 176.	0.5	10
89	OMALIZUMAB AS A THERAPEUTIC ALTERNATIVE FOR CHRONIC URTICARIA. Annals of Allergy, Asthma and Immunology, 2008, 101, 556.	0.5	9
90	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	1.0	9

#	Article	IF	Citations
91	Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis. Human Immunology, 2010, 71, 525-529.	1.2	9
92	Novel association of acid phosphatase locus 1*C allele with systemic lupus erythematosus. Human Immunology, 2012, 73, 107-110.	1.2	9
93	Manifestaciones otorrinolaringolÃ³gicas de las vasculitis sistÃ©micas. Acta OtorrinolaringolÃ³gica EspaÃ±ola, 2012, 63, 303-310.	0.2	9
94	Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	2.9	9
95	Lack of Association Between STAT4 Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2009, 36, 1021-1025.	1.0	8
96	Lack of Association Between TRAF1/C5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 131-135.	1.0	8
97	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. Journal of Rheumatology, 2012, 39, 112-118.	1.0	8
98	Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter crossâ€sectional study. International Journal of Rheumatic Diseases, 2018, 21, 2028-2035.	0.9	8
99	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
100	Sclerostin serum levels in patients with systemic autoimmune diseases. BoneKEy Reports, 2016, 5, 775.	2.7	8
101	Lack of association between IL6 gene and Henoch-SchÃ¶nlein purpura. Clinical and Experimental Rheumatology, 2014, 32, S141-2.	0.4	8
102	Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 98-105.	0.4	8
103	Association between perceived level of stress, clinical characteristics and psychopathological symptoms in women with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2018, 36, 434-441.	0.4	8
104	Lupus Pernio or Chilblain Lupus?. Chest, 2009, 136, 946-947.	0.4	7
105	Effectiveness of Mycophenolic Acid in Refractory Pyoderma Gangrenosum. Journal of Clinical Rheumatology, 2010, 16, 346-347.	0.5	7
106	Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis. Molecular Vision, 2013, 19, 638-43.	1.1	7
107	Alterations in episodic memory in patients with systemic lupus erythematosusâ˜†. Archives of Clinical Neuropsychology, 2008, 23, 157-64.	0.3	6
108	Specific association ofIL17Agenetic variants with panuveitis. British Journal of Ophthalmology, 2015, 99, 566-570.	2.1	6

#	Article	IF	Citations
109	Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 40-47.	0.4	6
110	Use of rituximab in Wegener's granulomatosis: comment on the article by Wong. Nephrology Dialysis Transplantation, 2007, 22, 958-959.	0.4	4
111	Role of BANK1 Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 1502-1504.	1.0	4
112	The Functional Polymorphism 844 A>G in FcÎ±RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. Journal of Rheumatology, 2011, 38, 446-449.	1.0	4
113	A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2011, 38, 2598-2601.	1.0	4
114	No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. PLoS ONE, 2013, 8, e72892.	1.1	4
115	Pulmonary Langerhans Histiocytosis: an uncommon cause of interstitial pneumonia in a patient with SjÃ¶gren syndrome. Clinical Rheumatology, 2016, 35, 825-828.	1.0	4
116	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	1.6	4
117	Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. Clinical and Experimental Rheumatology, 2011, 29, S12-6.	0.4	4
118	Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population. Clinical and Experimental Rheumatology, 2012, 30, S29-33.	0.4	4
119	Lack of association of TNFAIP3 and JAK1 with BehÃ§et's disease in the European population. Clinical and Experimental Rheumatology, 2015, 33, S36-9.	0.4	4
120	Pulmonary hypertension and exercise echocardiography. European Journal of Echocardiography, 2006, 7, 261-262.	2.3	3
121	Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2331-2333.	1.0	3
122	Two Functional Variants of IRF5 Influence the Development of Macular Edema in Patients with Non-Anterior Uveitis. PLoS ONE, 2013, 8, e76777.	1.1	3
123	Mesenteric Inflammatory Venoocclusive Disease in a Patient with SjÃ¶grenâ€™s Syndrome. Case Reports in Medicine, 2014, 2014, 1-3.	0.3	3
124	Etidronate and glucocorticoid induced osteoporosis. Journal of Rheumatology, 2005, 32, 199-200.	1.0	3
125	Long-Term Evolution of Cytophagic Histiocytic Panniculitis. Journal of Cutaneous Medicine and Surgery, 2010, 14, 136-140.	0.6	2
126	Association study ofBAK1gene polymorphisms in Spanish rheumatoid arthritis and systemic lupus erythematosus cohorts. Annals of the Rheumatic Diseases, 2012, 71, 314-316.	0.5	2

#	Article	IF	Citations
127	Influence of Psychological Stress on Headache in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 453-457.	1.0	2
128	Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis. Journal of Clinical Densitometry, 2021, 24, 362-368.	0.5	2
129	PTPN22 is not associated with BehÃ§et's disease. Study spanning the complete gene region in the Spanish population and meta-analysis of the functional variant R620W. Clinical and Experimental Rheumatology, 2016, 34, S41-S45.	0.4	2
130	Groove sign. European Journal of Internal Medicine, 2016, 28, e3-e4.	1.0	1
131	T Cell Large Granular Lymphocyte Leukaemia with Cutaneous Infiltration. Sultan Qaboos University Medical Journal, 2018, 17, 489.	0.3	1
132	Association of CCR5Î”32 and BehÃ§et's disease: new data from a case-control study in the Spanish population and meta-analysis. Clinical and Experimental Rheumatology, 2015, 33, S96-100.	0.4	1
133	Corticosteroids in preventing severe lupus flares: Do all patients have the same risk? Comment on the article by Tseng et al. Arthritis and Rheumatism, 2007, 56, 2098-2099.	6.7	0
134	A rare polymorphism in Toll Like Receptor 2 is associated with systemic sclerosis phenotype and increases production of inflammatory mediators. Journal of Translational Medicine, 2011, 9, .	1.8	0
135	Healthâ€Related Internet Use by Patients With Systemic Sclerosis and Other Autoimmune Diseases: Comment on the Article by van der Vaart et al. Arthritis Care and Research, 2014, 66, 334-334.	1.5	0
136	Enfermedad venooclusiva y esclerosis sistÃ©mica. Medicina ClÃ¬nica, 2017, 149, 320.	0.3	0
137	Low-Dose Rituximab for Hemolytic Anemia Retreatment in a Patient With Systemic Lupus Erythematosus. American Journal of Therapeutics, 2018, 25, e577-e578.	0.5	0
138	Eosinofilia, exantema pruriginoso y necrosis digital. Medicina ClÃ¬nica, 2018, 150, e17.	0.3	0
139	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. Clinical and Experimental Rheumatology, 2013, 31, 186.	0.4	0